DK1888031T3 - GLP-1-analogformuleringer - Google Patents

GLP-1-analogformuleringer

Info

Publication number
DK1888031T3
DK1888031T3 DK06744133.7T DK06744133T DK1888031T3 DK 1888031 T3 DK1888031 T3 DK 1888031T3 DK 06744133 T DK06744133 T DK 06744133T DK 1888031 T3 DK1888031 T3 DK 1888031T3
Authority
DK
Denmark
Prior art keywords
glp
analog formulations
formulations
analog
Prior art date
Application number
DK06744133.7T
Other languages
English (en)
Inventor
Fredrik Joabsson
Markus Johnsson
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2005/002217 external-priority patent/WO2005117830A1/en
Priority claimed from PCT/GB2005/004752 external-priority patent/WO2006075125A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Application granted granted Critical
Publication of DK1888031T3 publication Critical patent/DK1888031T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
DK06744133.7T 2005-06-06 2006-06-06 GLP-1-analogformuleringer DK1888031T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2005/002217 WO2005117830A1 (en) 2004-06-04 2005-06-06 Liquid depot formulations
PCT/GB2005/004752 WO2006075125A1 (en) 2005-01-14 2005-12-09 GnRH ANALOGUE FORMULATIONS
PCT/GB2006/002079 WO2006131730A1 (en) 2005-06-06 2006-06-06 Glp-1 analogue formulations

Publications (1)

Publication Number Publication Date
DK1888031T3 true DK1888031T3 (da) 2013-02-18

Family

ID=36741345

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06744133.7T DK1888031T3 (da) 2005-06-06 2006-06-06 GLP-1-analogformuleringer

Country Status (9)

Country Link
US (2) US8546326B2 (da)
EP (1) EP1888031B1 (da)
JP (1) JP5198261B2 (da)
CN (1) CN101217940B (da)
CA (1) CA2609810C (da)
DK (1) DK1888031T3 (da)
ES (1) ES2399645T3 (da)
PL (1) PL1888031T3 (da)
WO (1) WO2006131730A1 (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US9757461B2 (en) * 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
AU2005325510B2 (en) 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8299025B2 (en) * 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2886105B1 (en) * 2007-10-24 2018-12-05 Camurus Ab Controlled-release formulations
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
JP5744735B2 (ja) * 2008-09-04 2015-07-08 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 非水性担体を用いた徐放性製剤
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
CA2764418A1 (en) * 2009-06-25 2010-12-29 Sanofi-Aventis Deutschland Gmbh Cannula assembly for co-delivery of medicaments
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
US20120294855A1 (en) * 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
CN102597168B (zh) 2009-11-04 2014-09-03 默克专利股份有限公司 用于液晶介质的化合物及其用于高频组件的用途
PL3345593T3 (pl) * 2009-11-13 2024-04-08 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EA036213B1 (ru) * 2011-05-25 2020-10-14 Камурус Аб Пептидные композиции с контролируемым высвобождением
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
DE102011114986A1 (de) * 2011-09-28 2013-03-28 Ethris Gmbh Sprühsystem
EP2787974B1 (en) 2011-12-05 2017-05-24 Camurus Ab Robust controlled-release peptide formulations
EP2810657B1 (en) * 2012-01-31 2016-09-21 Santen Pharmaceutical Co., Ltd Non-aqueous liquid composition
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
KR102139080B1 (ko) 2012-05-25 2020-07-29 카무러스 에이비 소마토스타틴 수용체 작용제 제형
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
KR102374506B1 (ko) 2014-04-28 2022-03-15 오르포메드, 인코포레이티드 부프레노르핀 이량체 및 위장질환의 치료에서 그의 용도
CN111187338A (zh) 2014-06-12 2020-05-22 Ra制药公司 补体活性的调节
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
HRP20211824T1 (hr) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2016191395A1 (en) 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin(9-39)
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
HUE061759T2 (hu) 2015-12-16 2023-08-28 Ra Pharmaceuticals Inc Komplement aktivitás modulátorai
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017168435A1 (en) * 2016-03-31 2017-10-05 Sun Pharma Advanced Research Company Limited Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190083645A (ko) 2016-09-15 2019-07-12 카무러스 에이비 프로스타글란딘 유사체 제제
TWI805558B (zh) 2016-09-27 2023-06-21 瑞典商凱慕路斯公司 混合物與配方
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN108606957A (zh) * 2016-12-13 2018-10-02 南京星银药业集团有限公司 一种含索马鲁肽的口服缓释制剂及其制备方法
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
EP3842061A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
ES2133391T3 (es) 1991-10-04 1999-09-16 Gs Dev Ab Particulas, metodo para preparar dichas particulas y usos de las mismas.
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
EP0752855B1 (en) 1994-03-30 1999-06-09 Gs Development Ab Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
CA2231273A1 (en) 1995-10-12 1997-04-17 Lise Sylvest Nielsen A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
ATE272394T1 (de) * 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
EP0975331A1 (en) 1997-04-17 2000-02-02 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SI1140148T1 (sl) * 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
US6467987B1 (en) * 1999-03-29 2002-10-22 Honeywell International Inc. Resettable non-explosive actuator
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
CA2451432A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
EP1412384B1 (en) * 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
WO2003057235A2 (en) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
ATE411101T1 (de) 2003-08-04 2008-10-15 Camurus Ab Verfahren zum beladen von amphiphilen teilchen mit wirkstoffen
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
BRPI0414539B8 (pt) * 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
GB0325745D0 (en) * 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
DK1682091T3 (da) 2003-11-07 2017-05-15 Camurus Ab Sammensætninger af lipider og kationiske peptider
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
DE602005025083D1 (da) * 2004-01-23 2011-01-13 Camurus Ab
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
ATE401054T1 (de) 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
CA2575906C (en) 2004-08-04 2014-04-15 Camurus Ab Compositions forming non-lamellar dispersions
CA2594711C (en) 2005-01-14 2012-11-06 Camurus Ab Somatostatin analogue formulations
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
EP1845942B1 (en) 2005-01-14 2014-04-09 Camurus Ab Gnrh analogue formulations
US9757461B2 (en) 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
AU2005325510B2 (en) 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
JP5401095B2 (ja) 2005-11-17 2014-01-29 ゾゲニクス インコーポレーティッド 無針注射による粘性製剤の送達方法
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations

Also Published As

Publication number Publication date
CA2609810A1 (en) 2006-12-14
CN101217940A (zh) 2008-07-09
CA2609810C (en) 2012-05-22
US8097239B2 (en) 2012-01-17
WO2006131730A1 (en) 2006-12-14
JP5198261B2 (ja) 2013-05-15
JP2008542437A (ja) 2008-11-27
US20080146490A1 (en) 2008-06-19
US8546326B2 (en) 2013-10-01
PL1888031T3 (pl) 2013-04-30
EP1888031B1 (en) 2013-01-23
CN101217940B (zh) 2013-03-27
ES2399645T3 (es) 2013-04-02
US20080124394A1 (en) 2008-05-29
EP1888031A1 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
DK1888031T3 (da) GLP-1-analogformuleringer
NO20075628L (no) Farmasøytiske formuleringer
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
GB2424581B (en) Formulations
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK3295967T3 (da) Sårplejeindretning
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
SE0501138L (sv) Joystick arrangement
ZA200707654B (en) Formulations
IL192149A0 (en) Stable s-nitrosothiol formulations
DE602006006692D1 (de) Konzentrierte flüssige triazolfungizidformulierungen
NO20051756L (no) Stol
FR2880798B1 (fr) Fauteuil roulant
ITPD20050018A1 (it) Composizione insetticida
FI6942U1 (fi) Tuoli
FR2884411B1 (fr) Fauteuil roulant
FI20050938A0 (fi) Istuin
ES1060691Y (es) Ataud
EE200500025A (et) Rattakott
TH82724B (th) เก้าอี้
ITVI20050061A1 (it) Sedia
FI20050722A0 (fi) Tuoli